Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | SDHA | P31040 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CALML3 | P27482 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 4/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393510 | 0.92 | MAOA (0.49) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1393263 | 0.91 | MAOA (0.55) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL12075827 | 0.91 | MAOA (0.47) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL17752399 | 0.85 | MAOA (0.44) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1393974 | 0.84 | MAOA (0.57) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3094008 | 0.83 | MAOA (0.51) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1394103 | 0.82 | MAOA (0.56) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1394097 | 0.82 | MAOA (0.55) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL16562024 | 0.81 | MAOA (0.59) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4649596 | 0.81 | MAOA (0.49) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | MELINTA SUBSIDARY CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA SUBSIDIARY CORP. | 2016-05-19 | — | — | US | disclosed |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| EP-1656370-B1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB X PHARMACEUTICALS INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | RIB-X PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-7705026-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090118502-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-7456206-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456206-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456206-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7148219-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060264426-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2006-11-23 | — | — | US | disclosed |
| US-6969726-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-11-29 | — | — | US | disclosed |
| US-20050203147-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-09-15 | — | — | US | disclosed |
| US-20050043317-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264426-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | MAOA 872/4885MAOB 994/4885PTGS1 39/4885 |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | MAOA 872/4885MAOB 994/4885PTGS1 39/4885 |
| US-20050043317-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | MAOA 872/4885MAOB 994/4885PTGS1 39/4885 |
| US-20090118502-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | MAOA 872/4885MAOB 994/4885PTGS1 39/4885 |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | PCNA, AADAC, MIF | MAOA 872/4885MAOB 994/4885PTGS1 39/4885 |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | CUTA, CYP17A1, HSD17B11 | MAOA 1569/4885MAOB 1093/4885PTGS1 695/4885 |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | PCNA, AADAC, MIF | MAOA 872/4885MAOB 994/4885PTGS1 39/4885 |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | CUTA, CYP17A1, HSD17B11 | MAOA 1569/4885MAOB 1093/4885PTGS1 695/4885 |
| US-20050203147-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | MAOA 872/4885MAOB 994/4885PTGS1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.